WO2006040465A3 - Nouveau produit, procede et intermediaires de preparation de derives d'azetidine - Google Patents

Nouveau produit, procede et intermediaires de preparation de derives d'azetidine Download PDF

Info

Publication number
WO2006040465A3
WO2006040465A3 PCT/FR2005/002490 FR2005002490W WO2006040465A3 WO 2006040465 A3 WO2006040465 A3 WO 2006040465A3 FR 2005002490 W FR2005002490 W FR 2005002490W WO 2006040465 A3 WO2006040465 A3 WO 2006040465A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
intermediates
azetidine derivatives
novel product
azetidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2005/002490
Other languages
English (en)
Other versions
WO2006040465A2 (fr
Inventor
Stephane Mutti
Michel Lavigne
Luc Grondard
Joel Malpart
Joerg Rieke-Zapp
Veronique Crocq
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200700840A priority Critical patent/EA011408B1/ru
Priority to AU2005293454A priority patent/AU2005293454A1/en
Priority to MX2007003923A priority patent/MX2007003923A/es
Priority to EP05809232A priority patent/EP1805167A2/fr
Priority to CA002583992A priority patent/CA2583992A1/fr
Priority to BRPI0516507-5A priority patent/BRPI0516507A/pt
Priority to JP2007536214A priority patent/JP2008516932A/ja
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of WO2006040465A2 publication Critical patent/WO2006040465A2/fr
Publication of WO2006040465A3 publication Critical patent/WO2006040465A3/fr
Priority to IL181904A priority patent/IL181904A0/en
Priority to TNP2007000097A priority patent/TNSN07097A1/fr
Priority to EC2007007332A priority patent/ECSP077332A/es
Priority to US11/689,588 priority patent/US7687493B2/en
Anticipated expiration legal-status Critical
Priority to NO20072192A priority patent/NO20072192L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nouveau procédé de préparation de dérivés d'azétidine tels que le N-{1-[bis-(4-chlorophényl)méthyl]azétidin-3-yl}-N-quinol-6-yl-méthylsulfonamide et de son dichlorhydrate et du N-{1-[bis-(4-chlorophényl)méthyl]azétidin-3-yl}-N-(3,5-difluorophényl)-méthylsulfonamide.
PCT/FR2005/002490 2004-10-14 2005-10-10 Nouveau produit, procede et intermediaires de preparation de derives d'azetidine Ceased WO2006040465A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EA200700840A EA011408B1 (ru) 2004-10-14 2005-10-10 Новый продукт, способ и промежуточные продукты получения производных азетидина
AU2005293454A AU2005293454A1 (en) 2004-10-14 2005-10-10 Novel product, method and intermediates for the preparation of azetidine derivatives
MX2007003923A MX2007003923A (es) 2004-10-14 2005-10-10 Nuevo producto, procedimiento e intermediarios de preparacion de derivados de azetidina.
EP05809232A EP1805167A2 (fr) 2004-10-14 2005-10-10 Nouveau produit, procede et intermediaires de preparation de derives d'azetidine
CA002583992A CA2583992A1 (fr) 2004-10-14 2005-10-10 Nouveau produit, procede et intermediaires de preparation de derives d'azetidine
BRPI0516507-5A BRPI0516507A (pt) 2004-10-14 2005-10-10 produto, processo e intermediários de preparação de derivados de azetidina
JP2007536214A JP2008516932A (ja) 2004-10-14 2005-10-10 アゼチジン誘導体調製のための新規な生成物、方法および中間体
IL181904A IL181904A0 (en) 2004-10-14 2007-03-13 Novel product, method and intermediates for the preparation of azetidine derivatives
TNP2007000097A TNSN07097A1 (fr) 2004-10-14 2007-03-16 Nouveau produit, procede et intermediaires de preparation de derives d'azetidine
EC2007007332A ECSP077332A (es) 2004-10-14 2007-03-21 Nuevo producto, procedimiento e intermediarios de preparación de derivados de azetidina
US11/689,588 US7687493B2 (en) 2004-10-14 2007-03-22 Product, method and intermediates for the preparation of azetidine derivatives
NO20072192A NO20072192L (no) 2004-10-14 2007-04-27 Nytt produkt, fremgangsmate og mellomprodukter for fremstilling av azetidinderivater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0410844A FR2876688B1 (fr) 2004-10-14 2004-10-14 Nouveau produit, procede et intermediaires de preparation de derives d'azetidine
FR0410844 2004-10-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/689,588 Continuation US7687493B2 (en) 2004-10-14 2007-03-22 Product, method and intermediates for the preparation of azetidine derivatives

Publications (2)

Publication Number Publication Date
WO2006040465A2 WO2006040465A2 (fr) 2006-04-20
WO2006040465A3 true WO2006040465A3 (fr) 2006-08-10

Family

ID=34954419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/002490 Ceased WO2006040465A2 (fr) 2004-10-14 2005-10-10 Nouveau produit, procede et intermediaires de preparation de derives d'azetidine

Country Status (21)

Country Link
US (1) US7687493B2 (fr)
EP (1) EP1805167A2 (fr)
JP (1) JP2008516932A (fr)
KR (1) KR20070063544A (fr)
CN (1) CN101039931A (fr)
AR (1) AR051390A1 (fr)
AU (1) AU2005293454A1 (fr)
BR (1) BRPI0516507A (fr)
CA (1) CA2583992A1 (fr)
EA (1) EA011408B1 (fr)
EC (1) ECSP077332A (fr)
FR (1) FR2876688B1 (fr)
IL (1) IL181904A0 (fr)
MA (1) MA29513B1 (fr)
MX (1) MX2007003923A (fr)
NO (1) NO20072192L (fr)
SG (1) SG155193A1 (fr)
TN (1) TNSN07097A1 (fr)
TW (1) TW200630358A (fr)
WO (1) WO2006040465A2 (fr)
ZA (1) ZA200702528B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113045539B (zh) * 2021-03-30 2021-12-07 苏州大学 2-(4,4-二氯-1-(8-喹啉基)-2-氮杂环丁基)羧酸酯衍生物的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064634A1 (fr) * 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8709887D0 (en) * 1987-04-27 1987-06-03 Univ Alberta Alkyl azodicarboxylates
US5530134A (en) * 1994-09-06 1996-06-25 Synphar Laboratories Inc. Synthesis of anabaseine, salts and derivatives thereof
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
DK1308439T3 (da) * 2000-08-10 2009-01-12 Mitsubishi Tanabe Pharma Corp Prolinderivater og anvendelse af disse som lægemidler
US7825109B2 (en) * 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064634A1 (fr) * 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation

Also Published As

Publication number Publication date
MA29513B1 (fr) 2008-06-02
NO20072192L (no) 2007-04-27
BRPI0516507A (pt) 2008-09-16
WO2006040465A2 (fr) 2006-04-20
FR2876688B1 (fr) 2007-03-16
AR051390A1 (es) 2007-01-10
AU2005293454A1 (en) 2006-04-20
EA200700840A1 (ru) 2007-08-31
EP1805167A2 (fr) 2007-07-11
SG155193A1 (en) 2009-09-30
EA011408B1 (ru) 2009-02-27
KR20070063544A (ko) 2007-06-19
US7687493B2 (en) 2010-03-30
ZA200702528B (en) 2008-07-30
ECSP077332A (es) 2007-04-26
US20070270463A1 (en) 2007-11-22
FR2876688A1 (fr) 2006-04-21
IL181904A0 (en) 2007-07-04
TW200630358A (en) 2006-09-01
CA2583992A1 (fr) 2006-04-20
TNSN07097A1 (fr) 2008-06-02
JP2008516932A (ja) 2008-05-22
MX2007003923A (es) 2007-06-07
CN101039931A (zh) 2007-09-19

Similar Documents

Publication Publication Date Title
WO2003093269A3 (fr) Pyrazolopyrimidine-4-one substituee
SI1713475T1 (sl) Derivati 1,3,5-trisubstituirani 4,5-dihidro-1h-pirazola, ki imajo cb1-antagonistiäśno aktivnost
WO2003070725A3 (fr) Procede de preparation de derives de l'indolinone
WO2005000820A3 (fr) Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1
WO2006018222A8 (fr) Nouveaux hydrates et polymorphes du 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-4-6-oxo-2-piperidinyl]amino]-3-methoxy-n-(1-methyl-4-piperidinyl)-benzamide, son procede de production et son utilisation comme medicament
WO2007119106A3 (fr) Procédés de préparation de composés intermédiaires utilisés dans la préparation de l'ézétimibe
WO2008021804A3 (fr) Amides thérapeutiques et composés associés
TW200740769A (en) Novel process
WO2004056769A3 (fr) Synthèse d'amines et intermédiaires pour cette synthèse
WO2008074693A3 (fr) Procédé de préparation de 3,5-di-omicron-acyl-2-fluoro-2-c-méthyl-d-ribono-gamma-lactone
TW200745039A (en) Isotopically substituted pantoprazole
WO2004026224A3 (fr) Procede de preparation de derives de prostaglandine et matieres premieres mises en oeuvre dans ce procede
WO2005037780A3 (fr) Derives de 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2h-chrome-6-yl substitues par un amidomethyle, et medicaments renfermant ces composes
MXPA05012363A (es) Poliisocianatos bloqueados estables en la solidificacion.
ZA200303189B (en) Method for producing a piece of timber including heartwood.
WO2005042480A3 (fr) Pyrazolylcarboxanilides n-substitues
MX2007004483A (es) Metodo y productos intermediarios para la preparacion de derivados de n-(1-benzhidril-azetidin-3-il)-n- fenilmetilsulfonamida.
AU2003235814A1 (en) Novel process for the preparation of trans-3- ethyl-2,5- dihydro-4- methyl-n-(2-( 4-(((((4-methyl cyclohexyl) amino)carbonyl) amino)sulfonyl) phenyl)ethyl) -2-oxo-1h-pyrrole -1-carboxamide
WO2007073888A3 (fr) Composition pharmaceutique contenant de l'hydrochlorure de donepezil, comprime a base de cette composition et procede de production associe
MX2007003923A (es) Nuevo producto, procedimiento e intermediarios de preparacion de derivados de azetidina.
WO2003086281A3 (fr) Production de chitosane
EP1841739B8 (fr) Procédé de synthèse de la 1-benzyl-4-[(5,6-diméthoxy-1-indanon--2-yl)méthyl]pipéridine ou de son sel via un nouvel intermédiaire
WO2006036498A3 (fr) Procede de preparation de pyrazoles 1,3,5-trisubstitues par [3+2] cycloaddition
WO2006090265A3 (fr) Procedes de preparation de levetiracetam, son intermediaire et utilisation de levetiracetam dans des compositions pharmaceutiques
WO2003080567A3 (fr) Produits intermediaires destines a la synthese de la discodermolide et de ses analogues, et leurs procedes de preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 181904

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 553951

Country of ref document: NZ

Ref document number: 12007500619

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: DZP2007000188

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2005293454

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 11689588

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007/02528

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/003923

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1275/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2583992

Country of ref document: CA

Ref document number: 07036349

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2007536214

Country of ref document: JP

Ref document number: 200580035083.7

Country of ref document: CN

Ref document number: 1020077008461

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005293454

Country of ref document: AU

Date of ref document: 20051010

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005293454

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005809232

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1200700991

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 200700840

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2005809232

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11689588

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0516507

Country of ref document: BR